The last 10-Q has some bullish statements about the Freedom60: "Sales of the FREEDOM60(R) Syringe Infusion System, related accessories and repairs have become our company's lead product representing 52% of the company's total sales for the nine-months ending November 30, 2007 as compared to 40% for the period ended November 2006 with total sales, domestic and international, increasing by 83%. The performance from this period resulted from a management shift in sales strategy which included eliminating outside consulting and in-house sales personnel who were ineffective in driving any new revenues and relying instead on our in house staff. During the past year we decided to focus the majority of our efforts in the Freedom60 line, specifically towards the subcutaneous immune globulin (SCIG) market. We made decisions to directly support clinical trials by providing 42 Freedom60 pumps at our sole expense into a phase IV clinical trial. We attended fourteen SCIG nursing education programs. This has allowed us to meet hundreds of nurses all over the country who administer to the needs of this market. We applied for better reimbursement from Medicare for the Freedom60. Due to our direct efforts, reimbursement was increased twenty fold and subsequently resulted in Medicare issuing a letter of clarification stating the Freedom60 as the only pump approved for SCIG reimbursement. Lastly, we diligently called on, in-serviced and sold virtually every major SCIG provider in the country. We anticipate these sales to continue to increase as the SCIG market continues to develop and as we work on new enhancements to the Freedom60 that we believe will expand this market even further. In addition, many of the SCIG users will see benefit in using the Freedom60 system for other uses, such as antibiotics, chemotherapeutics and pain medications."
Mike
